Novartis earns third place in the 2016 Access to Medicine Index ranking (in 2014 it was in 4th position) which measures every two years the performance achieved by the top 20 pharmaceutical companies in improving access to medicines and healthcare in countries where developing. The assessment takes into account seven metrics, including drug access management, resource capacity development, pricing, manufacturing and distribution.
“Novartis,” said Joseph Jimenez, CEO of Novartis. shares the main objective of the Access to Medicine Index: to bridge the gap that penalizes access to medicines by developing countries. We are pleased that our activities have been recognised, but more needs to be done. To further improve access, we will continue to work on creating more scalable and sustainable approaches to improve the affordability and availability of medicines for patients in the most deprived conditions."
Novartis' efforts were recognized for two programs, in particular: Novartis Access, the portfolio of 15 covered and off-patent medicines to fight chronic diseases in low-income countries and ComHIP, a program supported by the Novartis Foundation and its partners to evaluate the impact of an innovative health care model for the control and self-management of hypertension in Ghana (Africa).
Related news: Access to Medicine Index 2016
Access to medicines, Johnson & Johnson second in the world
Gsk at the top of the Access to Medicine Index
